Results

Alnylam Pharmaceuticals Inc.

10/27/2021 | Press release | Distributed by Public on 10/27/2021 14:08

Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy